Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7519
- TODAY'S CHANGE (%)-0.0036 (-0.4765%)
- Bid / Lots0.7275/ 5
- Ask / Lots0.7798/ 3
- Open / Previous Close0.7460 / 0.7555
- Day Range
- 52 Week Range
- Volume192,151
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 937 | 0.755 |
| 09:34 ET | 1316 | 0.721 |
| 09:36 ET | 291 | 0.7222 |
| 09:41 ET | 500 | 0.745239 |
| 09:48 ET | 100 | 0.7215 |
| 09:54 ET | 100 | 0.72155 |
| 09:56 ET | 1000 | 0.7453 |
| 09:57 ET | 300 | 0.7216 |
| 09:59 ET | 200 | 0.745 |
| 10:06 ET | 7140 | 0.722 |
| 10:08 ET | 100 | 0.721 |
| 10:10 ET | 1100 | 0.7303 |
| 10:12 ET | 100 | 0.721 |
| 10:14 ET | 100 | 0.7395 |
| 10:15 ET | 200 | 0.721 |
| 10:17 ET | 300 | 0.722 |
| 10:19 ET | 100 | 0.7395 |
| 10:21 ET | 100 | 0.7395 |
| 10:24 ET | 514 | 0.7385 |
| 10:26 ET | 200 | 0.7395 |
| 10:28 ET | 300 | 0.735 |
| 10:30 ET | 100 | 0.7395 |
| 10:32 ET | 650 | 0.7212 |
| 10:33 ET | 100 | 0.7215 |
| 10:35 ET | 300 | 0.7395 |
| 10:37 ET | 200 | 0.7311 |
| 10:39 ET | 1587 | 0.7244 |
| 10:42 ET | 1232 | 0.7321 |
| 10:44 ET | 1387 | 0.7211 |
| 10:48 ET | 400 | 0.7321 |
| 10:50 ET | 1100 | 0.7321 |
| 10:51 ET | 100 | 0.7321 |
| 10:53 ET | 300 | 0.7294 |
| 10:55 ET | 2732 | 0.7298 |
| 10:57 ET | 9445 | 0.7321 |
| 11:00 ET | 100 | 0.7321 |
| 11:02 ET | 200 | 0.7321 |
| 11:04 ET | 200 | 0.7321 |
| 11:06 ET | 200 | 0.7321 |
| 11:08 ET | 200 | 0.7321 |
| 11:09 ET | 413 | 0.7321 |
| 11:11 ET | 500 | 0.7321 |
| 11:13 ET | 613 | 0.7321 |
| 11:18 ET | 100 | 0.7321 |
| 11:26 ET | 100 | 0.735 |
| 11:27 ET | 900 | 0.735 |
| 11:29 ET | 100 | 0.7375 |
| 11:33 ET | 100 | 0.7375 |
| 11:36 ET | 200 | 0.7375 |
| 11:38 ET | 200 | 0.7375 |
| 11:40 ET | 200 | 0.7375 |
| 11:42 ET | 100 | 0.7375 |
| 11:45 ET | 464 | 0.7375 |
| 11:49 ET | 1169 | 0.7375 |
| 11:51 ET | 100 | 0.7375 |
| 11:54 ET | 100 | 0.7375 |
| 12:05 ET | 500 | 0.7375 |
| 12:07 ET | 783 | 0.7341 |
| 12:09 ET | 200 | 0.7341 |
| 12:16 ET | 100 | 0.7341 |
| 12:20 ET | 100 | 0.723 |
| 12:21 ET | 100 | 0.7341 |
| 12:30 ET | 1000 | 0.7229 |
| 12:32 ET | 100 | 0.735 |
| 12:34 ET | 100 | 0.735 |
| 12:36 ET | 100 | 0.735 |
| 12:38 ET | 200 | 0.735 |
| 12:39 ET | 200 | 0.7375 |
| 12:41 ET | 100 | 0.7375 |
| 12:45 ET | 600 | 0.7375 |
| 12:48 ET | 100 | 0.7231 |
| 12:50 ET | 200 | 0.7375 |
| 12:54 ET | 100 | 0.7375 |
| 12:56 ET | 200 | 0.7375 |
| 01:01 ET | 1406 | 0.7375 |
| 01:06 ET | 1010 | 0.7375 |
| 01:08 ET | 363 | 0.73375 |
| 01:10 ET | 100 | 0.7375 |
| 01:12 ET | 100 | 0.7375 |
| 01:14 ET | 600 | 0.73 |
| 01:15 ET | 200 | 0.7295 |
| 01:26 ET | 300 | 0.73 |
| 01:30 ET | 400 | 0.73 |
| 01:33 ET | 400 | 0.729899 |
| 01:37 ET | 1625 | 0.721 |
| 01:42 ET | 4100 | 0.749 |
| 01:44 ET | 4987 | 0.749 |
| 01:46 ET | 100 | 0.7496 |
| 01:48 ET | 3883 | 0.76 |
| 01:50 ET | 800 | 0.7575 |
| 01:51 ET | 400 | 0.7574 |
| 01:53 ET | 300 | 0.7575 |
| 01:55 ET | 1200 | 0.75125 |
| 01:57 ET | 300 | 0.7575 |
| 02:00 ET | 3400 | 0.7515 |
| 02:02 ET | 700 | 0.75 |
| 02:04 ET | 300 | 0.7542 |
| 02:06 ET | 600 | 0.7575 |
| 02:08 ET | 300 | 0.7575 |
| 02:09 ET | 740 | 0.76 |
| 02:11 ET | 400 | 0.76 |
| 02:13 ET | 7981 | 0.76 |
| 02:15 ET | 400 | 0.747 |
| 02:18 ET | 5500 | 0.7769 |
| 02:20 ET | 400 | 0.7793 |
| 02:22 ET | 2500 | 0.7794 |
| 02:24 ET | 550 | 0.7794 |
| 02:26 ET | 400 | 0.7787 |
| 02:27 ET | 300 | 0.7786 |
| 02:29 ET | 650 | 0.77 |
| 02:31 ET | 4900 | 0.7772 |
| 02:33 ET | 601 | 0.764 |
| 02:36 ET | 300 | 0.7788 |
| 02:38 ET | 500 | 0.7788 |
| 02:40 ET | 400 | 0.7788 |
| 02:42 ET | 300 | 0.7788 |
| 02:44 ET | 3725 | 0.7794 |
| 02:45 ET | 800 | 0.7794 |
| 02:47 ET | 400 | 0.7794 |
| 02:49 ET | 200 | 0.7794 |
| 02:51 ET | 300 | 0.78 |
| 02:54 ET | 300 | 0.78 |
| 02:56 ET | 1000 | 0.78 |
| 02:58 ET | 1656 | 0.78 |
| 03:00 ET | 400 | 0.78 |
| 03:02 ET | 200 | 0.78 |
| 03:03 ET | 300 | 0.78 |
| 03:05 ET | 400 | 0.78 |
| 03:07 ET | 434 | 0.78 |
| 03:09 ET | 527 | 0.78 |
| 03:12 ET | 300 | 0.78 |
| 03:14 ET | 432 | 0.775 |
| 03:16 ET | 247 | 0.775 |
| 03:18 ET | 5550 | 0.7747 |
| 03:20 ET | 660 | 0.7747 |
| 03:21 ET | 100 | 0.774 |
| 03:23 ET | 300 | 0.7717 |
| 03:25 ET | 350 | 0.7707 |
| 03:27 ET | 100 | 0.775 |
| 03:30 ET | 532 | 0.762 |
| 03:32 ET | 665 | 0.7621 |
| 03:34 ET | 200 | 0.76875 |
| 03:36 ET | 816 | 0.76905 |
| 03:38 ET | 851 | 0.7692 |
| 03:39 ET | 620 | 0.76945 |
| 03:41 ET | 5731 | 0.775 |
| 03:43 ET | 6500 | 0.7744 |
| 03:45 ET | 1934 | 0.77435 |
| 03:48 ET | 600 | 0.7713 |
| 03:50 ET | 500 | 0.7647 |
| 03:52 ET | 2888 | 0.7661 |
| 03:54 ET | 400 | 0.767 |
| 03:56 ET | 2100 | 0.7666 |
| 03:57 ET | 1859 | 0.7665 |
| 03:59 ET | 620 | 0.7519 |
Apr 10, 2024
DJ Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham, from 6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 41.3M | -0.3x | --- |
Prenetics Global Ltd | 54.3M | -1.1x | --- |
ImmuCell Corp | 39.5M | -6.6x | --- |
Aadi Bioscience Inc | 45.7M | -0.8x | --- |
Turnstone Biologics Corp | 61.5M | -1.0x | --- |
Viaderma Inc | 12.3M | 0.0x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Senior Vice President - Research and Development, Chief Scientific Officer
- Frederique Menzaghi
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.3M |
|---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
